MOONLAKE IMMUNOTHERAPEUTICS (MLTX) Stock Earnings & Estimates
NASDAQ:MLTX - KY61559X1045 - Common Stock
59.44 USD
-0.28 (-0.47%)
59.44 USD
0 (0%)
Full estimates are only available for subscribed users, you can see which data is available below.
Subscribed users also see more surprise data, now it is restricted to 4 quarters.
Examples of complete estimate data are available for MSFT and AAPL.
Registered users have access to more data. Please register or login for additional estimates and surprises .
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY % growth | N/A | N/A | N/A | N/A 475.49% | N/A 104.58% | N/A 64.18% | N/A 0.12% | N/A 24.27% | |||||||
| EBITDA YoY % growth | N/A | N/A | -53.58M | -65.05M -21.41% | -54.11M 16.82% | -141.706M -161.89% | N/A -52.50% | N/A -22.44% | N/A -18.13% | N/A | N/A | N/A | N/A | N/A | |
| EBIT YoY % growth | -105.76K | -53.58M -50,561.88% | -65.06M -21.43% | -54.123M 16.81% | -143.091M -164.38% | N/A -66.52% | N/A -20.65% | N/A -12.89% | N/A 108.01% | N/A 1,664.68% | N/A 131.34% | N/A -11.80% | N/A 35.18% | ||
| Operating Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | |
| EPS YoY % growth | N/A | N/A | N/A | N/A | -0.76 49.48% | -1.89 -148.68% | N/A -77.80% | N/A -21.93% | N/A -0.36% | N/A 76.74% | N/A 322.40% | N/A 163.55% | N/A 15.01% | N/A 56.01% |
All data in USD
| Q3 / 25 | Q4 / 25 | Q1 / 26 | Q2 / 26 | Q3 / 26 | Q4 / 26 | |
|---|---|---|---|---|---|---|
| EPS Q2Q % growth | -0.89 -58.19% | -0.90 -25.52% | -0.94 -49.92% | -0.98 -12.08% | -0.99 -11.69% | -1.03 -13.71% |
| Revenue Q2Q % growth | ||||||
| EBITDA Q2Q % growth | -64.741M -50.46% | -67.747M -40.57% | N/A | N/A | N/A | N/A |
| EBIT Q2Q % growth | -63.428M -47.12% | -64.966M -31.03% | -65.499M -37.94% | -66.012M -8.75% | -69.309M -9.27% | -71.604M -10.22% |
All data in USD
| Period | Reported | Estimate | Difference | Surprise |
|---|---|---|---|---|
| Q2 2025 Q2Q % growth | -0.87 -123.08% | -0.74 | -0.13 | -18.26% |
| Q1 2025 Q2Q % growth | -0.63 -186.36% | -0.77 | 0.14 | 17.89% |
| Q4 2024 Q2Q % growth | -0.72 -500.00% | -0.61 | -0.11 | -18.11% |
| Q3 2024 Q2Q % growth | -0.56 -211.11% | -0.44 | -0.12 | -26.10% |
| Q2 2024 Q2Q % growth | -0.39 -69.57% | -0.28 | -0.11 | -37.92% |
| Q1 2024 Q2Q % growth | -0.22 4.35% | -0.20 | -0.02 | -11.55% |
| Q4 2023 Q2Q % growth | -0.12 61.29% | -0.23 | 0.11 | 48.88% |
| Q3 2023 Q2Q % growth | -0.18 33.33% | -0.23 | 0.05 | 22.46% |
| Q2 2023 Q2Q % growth | -0.23 32.35% | -0.27 | 0.04 | 15.13% |
| Q1 2023 Q2Q % growth | -0.23 | -0.32 | 0.09 | 27.32% |
| Q4 2022 Q2Q % growth | -0.31 | -0.33 | 0.02 | 7.18% |
| Q3 2022 Q2Q % growth | -0.27 | -0.33 | 0.06 | 17.45% |
| Q2 2022 Q2Q % growth | -0.34 | -0.55 | 0.21 | 38.27% |
| Period | Reported | Estimate | Difference | Surprise |
|---|
| Next Q (1 month) | Next Q (3 month) | Next Year (1 month) | Next Year (3 month) | |
|---|---|---|---|---|
| EPS | -17.55% | -19.7% | -14.69% | -13.42% |
| Revenue | N/A | N/A | N/A | N/A |